A Long-Term, Open-Label Extension Study to Investigate the Long-Term Safety of SYR110322 (SYR-322) in Subjects with Type 2 Diabetes

Registry ID
EUCTR2005-004672-20
Source registry
EUCTR
Status
Completed
Phase
PHASE3
Sponsor
Takeda Global Research & Development Center, Inc.,
Start date
2006-04-24
Last update
2026-08-16

Conditions

Summary

• To evaluate the safety of SYR-322 administered alone or in combination with a sulfonylurea, metformin, a thiazolidinedione, or insulin by evaluating adverse events (AEs), clinical laboratory parameters, electrocardiogram (ECG) readings, vital sign measurements, oral temperature, physical examinations, and hypoglycemic events

Locations

View on source registry